New Options For Achieving Glycemic Targets In T1 Diabetes: SGLT Inhibition
This interactive web activity provides an update on the efficacy of sodium-glucose co-transporter (SGLT) inhibitors for the treatment of patients with type 1 diabetes. The activity reviews clinical trial data on efficacy including study design and impact on HbA1C, weight, total daily insulin dose, and “time in range” with continuous glucose monitoring. Please see the infographic section for additional materials including the mechanism of action for SGLT inhibitors.
This activity has been designed to meet the educational needs of endocrinologists and other healthcare professionals involved in the diagnosis, treatment, or management of patients with T1D.
Upon completion of this activity, participants will be better able to do the following:
- Describe currently available adjunctive options for glycemic control.
- Evaluate the clinical trial data on the safety, efficacy, and potential clinical use of new and emerging sodium-glucose cotransporter (SGLT) 1 and 2 inhibitors in patients with Type 1 diabetes.
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|John B. Buse, MD, PhD||
Consultant/Advisor: Neurimmune AG
Grant/Research Support: Novo Nordisk A/S, Sanofi, and vTv Therapeutics.
Sandy Breslow, Alison Kemp, Bernard M. Abrams, MD, Marilu Kelly, MSN, RN, CNE, Louis Settembrino, CHCP, and Christina M. Ohnsman, MD hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Sanofi US and Lexicon Pharmaceuticals, Inc.
Jointly provided by the Elsevier Office of Continuing Medical Education, Elsevier, and Catalyst Medical Education, LLC.
CME/CE CREDIT (PHYSICIANS)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Catalyst Medical Education, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE CREDIT (NURSES)
This continuing nursing education activity, provided by Elsevier, awards 0.75 contact hour for nurses. Elsevier is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
CME/CE INQUIRIES/SPECIAL NEEDS
For all CME/CE inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Elsevier, Catalyst Medical Education, LLC., and Sanofi US and Lexicon Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of participation
In order to claim credit, participants must complete the following:
- Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions.
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Nurses who attain a grade of 70% on the post-activity test question and who complete the evaluation before the expiration date will receive a certificate of completion for 0.75 contact hour. There is no partial credit will be awarded for this activity.
- Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
Release date: October 31, 2018
Expiration date: October 31, 2019